FY2030 Earnings Forecast for CORT Issued By HC Wainwright

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Research analysts at HC Wainwright decreased their FY2030 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a note issued to investors on Wednesday, February 25th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of $7.19 per share for the year, down from their prior forecast of $7.74. HC Wainwright currently has a “Buy” rating and a $67.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). The business had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a return on equity of 15.18% and a net margin of 12.96%.Corcept Therapeutics’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter last year, the company earned $0.26 EPS.

A number of other equities research analysts also recently issued reports on CORT. Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. UBS Group initiated coverage on Corcept Therapeutics in a report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price target for the company. Truist Financial set a $50.00 price objective on Corcept Therapeutics in a research note on Wednesday, December 31st. Finally, Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a research report on Wednesday, December 31st. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $77.17.

Corcept Therapeutics Stock Down 0.7%

Shares of CORT stock opened at $36.22 on Thursday. The company has a current ratio of 3.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $117.33. The stock has a market cap of $3.81 billion, a P/E ratio of 44.17 and a beta of 0.25. The company has a 50 day simple moving average of $46.29 and a two-hundred day simple moving average of $66.23.

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Abacus FCF Advisors LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at approximately $3,238,000. Pacer Advisors Inc. raised its holdings in Corcept Therapeutics by 6,796.7% during the 3rd quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock valued at $32,459,000 after buying an additional 384,896 shares during the period. Brown Capital Management LLC purchased a new stake in Corcept Therapeutics during the 3rd quarter valued at $19,950,000. Cerity Partners LLC lifted its position in Corcept Therapeutics by 21.4% in the second quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company’s stock worth $54,800,000 after buying an additional 131,799 shares during the last quarter. Finally, Synergy Asset Management LLC boosted its stake in Corcept Therapeutics by 96.1% during the third quarter. Synergy Asset Management LLC now owns 506,856 shares of the biotechnology company’s stock worth $39,615,000 after buying an additional 248,362 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.52, for a total transaction of $1,590,400.00. Following the completion of the sale, the insider directly owned 7,904 shares of the company’s stock, valued at $628,526.08. This trade represents a 71.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.53, for a total transaction of $397,650.00. Following the sale, the insider owned 10,277 shares in the company, valued at approximately $817,329.81. The trade was a 32.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 125,000 shares of company stock worth $8,301,450 over the last quarter. Company insiders own 20.80% of the company’s stock.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Company issued 2026 revenue guidance of $900M–$1.0B and management signaled optimism about relacorilant’s near-term oncology approval, which underpins the growth story if approval and launches go smoothly. Read More.
• Neutral Sentiment: HC Wainwright reduced its FY2030 EPS projection (from $7.74 to $7.19) but maintained a Buy rating and $67 price target — a mixed signal reflecting lower long-term expectations while keeping upside potential. Read More.
• Negative Sentiment: Q4 results missed estimates: EPS $0.20 vs. consensus ~$0.33 and revenue $202.1M vs. ~$255M — sales rose year-over-year but underwhelmed street expectations, which pressured the stock. Read More.
• Negative Sentiment: Numerous law firms have announced or are seeking plaintiffs in securities class actions alleging failures around disclosures related to relacorilant and FDA concerns; litigation risk and potential settlements increase uncertainty and can weigh on the stock. Read More.
• Neutral Sentiment: Analyst and media coverage is mixed: some pieces highlight an inflection point and upside from relacorilant, while others focus on the recent 50% share decline and evidence gaps cited by regulators — expect continued volatility as newsflow on the NDA and litigation develops. Read More.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.